GSK Signs Aptamer Deal With Archemix | January 5, 2009 Issue - Vol. 87 Issue 1 | Chemical & Engineering News
Volume 87 Issue 1 | p. 14 | Concentrates
Issue Date: January 5, 2009

GSK Signs Aptamer Deal With Archemix

Department: Business

GlaxoSmithKline has linked with Archemix to develop aptamer therapeutics, or synthesized oligonucleotides, against seven targets related to inflammatory diseases. GSK is taking a $6.5 million stake in Archemix, which recently announced a merger with fellow Boston-area biotech firm NitroMed. Archemix also gains an additional $21 million upfront and could receive up to $200 million in milestone payments for each of the seven aptamer targets covered in the deal. The biotech firm will be tasked with developing the aptamer therapeutics through clinical proof-of-mechanism.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment